Our group studies the signaling and structural mechanisms employed by RAS superfamily GTPases to regulate critical cellular processes (e.g., proliferation, motility, morphogenesis and apoptosis) and how these GTPases act to promote human malignancies when deregulated. We use a combination of biochemical, biophysical, structural and cell biological approaches to fully elucidate these mechanisms. We are especially focused on the RAS (HRAS, KRAS, NRAS) and RHO (RHOA, RAC1, CDC42) GTPase families. The activities of these GTPases and their accessory proteins are altered in over 30% of all human cancers and are also altered in several rare developmental disorders termed “RASopathies”. Our ultimate goal is to not only understand the unique signaling properties of RAS and RHO GTPases, but to discover how to manipulate these signaling pathways pharmacologically to treat cancer and other diseases.